{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T20:33:54Z","timestamp":1778704434135,"version":"3.51.4"},"reference-count":70,"publisher":"Informa UK Limited","issue":"6","funder":[{"name":"The Royal Australasian College of Physicians and Rotary International"},{"name":"AstraZeneca"},{"name":"Bayer"},{"name":"Boehringer Ingelheim"},{"name":"Bristol-Myers-Squibb"},{"DOI":"10.13039\/501100022274","name":"Daiichi Sankyo","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100022274","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Eli Lilly"},{"name":"GlaxoSmithKline"},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Janssen"},{"DOI":"10.13039\/100004339","name":"Sanofi-Aventis","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Cardiol."],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.2217\/fca-2020-0068","type":"journal-article","created":{"date-parts":[[2020,7,7]],"date-time":"2020-07-07T12:33:41Z","timestamp":1594125221000},"page":"597-611","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["Rivaroxaban for the Prevention of Major Adverse Cardiovascular Events in Patients with Coronary or Peripheral Artery Disease"],"prefix":"10.1080","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1029-1334","authenticated-orcid":false,"given":"Matt","family":"Wheeler","sequence":"first","affiliation":[{"name":"Population Health Research Institute, Hamilton, ON, L8L 2X2, Canada"},{"name":"McMaster University, Department of Medicine, Ontario, CanadaHamilton, ON, L8S 4L8, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noel","family":"Chan","sequence":"additional","affiliation":[{"name":"Population Health Research Institute, Hamilton, ON, L8L 2X2, Canada"},{"name":"Thrombosis & Atherosclerosis Research Institute\r          Hamilton, ON, L8L 2X2, Canada"},{"name":"McMaster University, Department of Medicine, Ontario, CanadaHamilton, ON, L8S 4L8, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4126-1285","authenticated-orcid":false,"given":"John","family":"Eikelboom","sequence":"additional","affiliation":[{"name":"Population Health Research Institute, Hamilton, ON, L8L 2X2, Canada"},{"name":"Thrombosis & Atherosclerosis Research Institute\r          Hamilton, ON, L8L 2X2, Canada"},{"name":"McMaster University, Department of Medicine, Ontario, CanadaHamilton, ON, L8S 4L8, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2020,7,7]]},"reference":[{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.115.307611"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000659"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2010.1322"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2017.06.001"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60503-1"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709118"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa060989"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa065959"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1409312"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1500857"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908077"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.832139"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehr113"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60738-8"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112277"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2000052"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1177\/1074248415578172"},{"issue":"8","key":"e_1_3_2_20_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1161\/JAHA.116.003553","article-title":"Thrombin generation and atherothrombosis: what does the evidence indicate?","volume":"5","author":"Ten Cate H","year":"2016","unstructured":"Ten Cate H , HemkerHC. Thrombin generation and atherothrombosis: what does the evidence indicate?J. Am. Heart Assoc.5(8), 1\u20138 (2016).","journal-title":"J. Am. Heart Assoc."},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1538-7836.2003.00298.x"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-40602-w"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2018.1495559"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-013-0100-7"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2005.06.011"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-005-0043-5"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.5414\/CP201812"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270006286904"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12075"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.2174\/138920008784220664"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3185"},{"key":"e_1_3_2_32_1","unstructured":"Xarelto dosing guide (2020). https:\/\/www.xarelto.com\/sites\/g\/files\/kmftyc361\/files\/2018-11\/dosing-guide-xarelto-effective-protection-indications-worldwide-09-2018.pdf"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.03.041"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1808848"},{"key":"e_1_3_2_35_1","volume-title":"Presented at: ESC.","author":"Zannad F","year":"2018","unstructured":"Zannad F . Rivaroxaban in patients with heart failure, sinus rhythm, and coronary disease. Presented at: ESC.Munich, Germany (2018). http:\/\/clinicaltrialresults.org\/Slides\/ESC2018\/COMMANDER_Zannad.pdf"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.04.041"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.07.065"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.119.041949"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32458-3"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32409-1"},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.119.039609"},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.035864"},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.02.048"},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.03.008"},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.10.048"},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2005.11.004"},{"key":"e_1_3_2_47_1","volume-title":"Classification and Regression Trees.","author":"Breiman L","year":"1984","unstructured":"Breiman L , FriedmanJ , StoneC , OlshenR. Classification and Regression Trees.Chapman & Hall\/CRC Taylor & Francis, FL, USA, (1984)."},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.02.079"},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2012.01.014"},{"key":"e_1_3_2_50_1","doi-asserted-by":"publisher","DOI":"10.1177\/1747493018784478"},{"key":"e_1_3_2_51_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2019.1049"},{"key":"e_1_3_2_52_1","doi-asserted-by":"publisher","DOI":"10.1177\/2047487319882154"},{"key":"e_1_3_2_53_1","unstructured":"EMA : Xarelto (2020). https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/xarelto"},{"key":"e_1_3_2_54_1","unstructured":"US FDA : Drugs@FDA: FDA-Approved Drugs (2020). https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=022406"},{"key":"e_1_3_2_55_1","unstructured":"Ollendorf D . McQueenR . FazioliKet al. Additive Therapies for Cardiovascular Disease: Effectiveness and Value Institute for Clinical and Economic Review: additive therapies for cardiovascular disease: effectiveness and value. (2019). http:\/\/icer-review.org\/material\/cvd-final-evidence-report\/"},{"key":"e_1_3_2_56_1","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvz278"},{"key":"e_1_3_2_57_1","unstructured":"Canadian Agency for Drugs and Technologies in Health Common Drug Review . Pharmacoecominic review report: rivaroxaban (Xarelto) in combination with 75 mg to 100 mg acetylsalicylic acid (ASA) for the prevention of stroke myocardial infarction and cardiovascular death and for the prevention of acute limb ischemia and mortality in patients with coronary artery disease (CAD) with or without peripheral artery disease (PAD). https:\/\/www.cadth.ca\/sites\/default\/files\/cdr\/clinical\/SR0569_Xarelto_CL_Report.pdf"},{"key":"e_1_3_2_58_1","doi-asserted-by":"publisher","DOI":"10.1177\/2047487318817910"},{"key":"e_1_3_2_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30751-1"},{"key":"e_1_3_2_60_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0904327"},{"key":"e_1_3_2_61_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000134"},{"key":"e_1_3_2_62_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0b013e3182742c84"},{"key":"e_1_3_2_63_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000404"},{"key":"e_1_3_2_64_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11886-019-1198-5"},{"key":"e_1_3_2_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.11.007"},{"key":"e_1_3_2_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2018.01.011"},{"key":"e_1_3_2_67_1","unstructured":"Post-Bleed Management Of Antithrombotic Therapy (PANTHER) research program overview: CanVECTOR. https:\/\/www.canvector.ca\/research\/foundational-platforms-research\/training-mentoring-and-early-career-development\/panther-research-program-overview-may-18-18.pdf"},{"key":"e_1_3_2_68_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx658"},{"issue":"1","key":"e_1_3_2_69_1","first-page":"13","article-title":"Use of risk score to identify lower and higher risk subsets among COMPASS-Eligible patients with stable CAD. Insights from the CLARIFY Registry","volume":"12","author":"Darmon A","year":"2020","unstructured":"Darmon A , DucrocqG , JasilekAet al. Use of risk score to identify lower and higher risk subsets among COMPASS-Eligible patients with stable CAD. Insights from the CLARIFY Registry. Arch. Cardiovasc. Dis. Suppl.12(1), 13 (2020).","journal-title":"Arch. Cardiovasc. Dis. Suppl."},{"key":"e_1_3_2_70_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1802686"},{"key":"e_1_3_2_71_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1813959"},{"key":"e_1_3_2_72_1","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.118.310960"}],"container-title":["Future Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fca-2020-0068","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T10:29:34Z","timestamp":1715941774000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fca-2020-0068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,7]]},"references-count":70,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["10.2217\/fca-2020-0068"],"URL":"https:\/\/doi.org\/10.2217\/fca-2020-0068","relation":{},"ISSN":["1479-6678","1744-8298"],"issn-type":[{"value":"1479-6678","type":"print"},{"value":"1744-8298","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,7]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifca20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifca20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-05-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-04","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}